Trial Profile
A Multicenter, Open-Label, Phase II Study of LEP-ETU for Efficacy and Safety in Patients With Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2011 Planned End Date changed from 1 Mar 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 04 Apr 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.